234 related articles for article (PubMed ID: 31757767)
1. Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies.
Zhu X; Turner HL; Lang S; McBride R; Bangaru S; Gilchuk IM; Yu W; Paulson JC; Crowe JE; Ward AB; Wilson IA
Cell Host Microbe; 2019 Dec; 26(6):729-738.e4. PubMed ID: 31757767
[TBL] [Abstract][Full Text] [Related]
2. Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice.
Gilchuk IM; Bangaru S; Gilchuk P; Irving RP; Kose N; Bombardi RG; Thornburg NJ; Creech CB; Edwards KM; Li S; Turner HL; Yu W; Zhu X; Wilson IA; Ward AB; Crowe JE
Cell Host Microbe; 2019 Dec; 26(6):715-728.e8. PubMed ID: 31757769
[TBL] [Abstract][Full Text] [Related]
3. An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.
Wilson JR; Guo Z; Reber A; Kamal RP; Music N; Gansebom S; Bai Y; Levine M; Carney P; Tzeng WP; Stevens J; York IA
Antiviral Res; 2016 Nov; 135():48-55. PubMed ID: 27713074
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Modification of an Anti-neuraminidase Human Antibody Restores Protection Efficacy against the Drifted Influenza Virus.
Jiang H; Peng W; Qi J; Chai Y; Song H; Bi Y; Rijal P; Wang H; Oladejo BO; Liu J; Shi Y; Gao GF; Townsend AR; Wu Y
mBio; 2020 Oct; 11(5):. PubMed ID: 33024040
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection.
Wan H; Qi L; Gao J; Couzens LK; Jiang L; Gao Y; Sheng ZM; Fong S; Hahn M; Khurana S; Taubenberger JK; Eichelberger MC
J Virol; 2018 Feb; 92(4):. PubMed ID: 29167344
[TBL] [Abstract][Full Text] [Related]
6. Protective efficacy of anti-neuraminidase monoclonal antibodies against H7N9 influenza virus infection.
Xiong FF; Liu XY; Gao FX; Luo J; Duan P; Tan WS; Chen Z
Emerg Microbes Infect; 2020; 9(1):78-87. PubMed ID: 31894728
[TBL] [Abstract][Full Text] [Related]
7. Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.
Job ER; Schotsaert M; Ibañez LI; Smet A; Ysenbaert T; Roose K; Dai M; de Haan CAM; Kleanthous H; Vogel TU; Saelens X
J Virol; 2018 Feb; 92(4):. PubMed ID: 29167342
[TBL] [Abstract][Full Text] [Related]
8. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
Walz L; Kays SK; Zimmer G; von Messling V
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
[TBL] [Abstract][Full Text] [Related]
9. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
10. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase.
Jiang L; Fantoni G; Couzens L; Gao J; Plant E; Ye Z; Eichelberger MC; Wan H
J Virol; 2016 Jan; 90(1):117-28. PubMed ID: 26468531
[TBL] [Abstract][Full Text] [Related]
12. Specific Monoclonal Antibodies Targeting Unique HA Epitopes Block H7N9 Influenza A Viral Replication.
Shen W; Wang Q; Wang Z; Liu M; Du Y; Yuan L; Han L; Smietanka K; Chen H; Xu S; Zhu Q
J Virol; 2022 Sep; 96(18):e0123822. PubMed ID: 36037479
[TBL] [Abstract][Full Text] [Related]
13. Fcγ Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies.
Job ER; Ysenbaert T; Smet A; Van Hecke A; Meuris L; Kleanthous H; Saelens X; Vogel TU
mBio; 2019 Oct; 10(5):. PubMed ID: 31641082
[TBL] [Abstract][Full Text] [Related]
14. Human neutralizing antibodies target a conserved lateral patch on H7N9 hemagglutinin head.
Jia M; Zhao H; Morano NC; Lu H; Lui YM; Du H; Becker JE; Yuen KY; Ho DD; Kwong PD; Shapiro L; To KK; Wu X
Nat Commun; 2024 May; 15(1):4505. PubMed ID: 38802413
[TBL] [Abstract][Full Text] [Related]
15. Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase.
Lederhofer J; Tsybovsky Y; Nguyen L; Raab JE; Creanga A; Stephens T; Gillespie RA; Syeda HZ; Fisher BE; Skertic M; Yap C; Schaub AJ; Rawi R; Kwong PD; Graham BS; McDermott AB; Andrews SF; King NP; Kanekiyo M
Immunity; 2024 Mar; 57(3):574-586.e7. PubMed ID: 38430907
[TBL] [Abstract][Full Text] [Related]
16. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
17. An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge.
Wilson JR; Belser JA; DaSilva J; Guo Z; Sun X; Gansebom S; Bai Y; Stark TJ; Chang J; Carney P; Levine MZ; Barnes J; Stevens J; Maines TR; Tumpey TM; York IA
Virology; 2017 Nov; 511():214-221. PubMed ID: 28888111
[TBL] [Abstract][Full Text] [Related]
18. Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice.
Wohlbold TJ; Chromikova V; Tan GS; Meade P; Amanat F; Comella P; Hirsh A; Krammer F
J Virol; 2016 Jan; 90(2):851-61. PubMed ID: 26512088
[TBL] [Abstract][Full Text] [Related]
19. Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.
Itoh Y; Shichinohe S; Nakayama M; Igarashi M; Ishii A; Ishigaki H; Ishida H; Kitagawa N; Sasamura T; Shiohara M; Doi M; Tsuchiya H; Nakamura S; Okamatsu M; Sakoda Y; Kida H; Ogasawara K
Antimicrob Agents Chemother; 2015 Aug; 59(8):4962-73. PubMed ID: 26055368
[TBL] [Abstract][Full Text] [Related]
20. A cross-reactive human monoclonal antibody targets the conserved H7 antigenic site A from fifth wave H7N9-infected humans.
Li M; Chen L; Wang Q; Hao M; Zhang X; Liu L; Yu X; Yang C; Xu J; Chen J; Gong R
Antiviral Res; 2019 Oct; 170():104556. PubMed ID: 31299269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
